XOMA Royalty Stock Quote XOMA - Stock Price, News, Charts, Message Board, Trades

Empower your portfolio: Real-time discussions and actionable trading ideas.

Premium

Current Price

28.98

Bid

28.40

Ask

30.00

Volume

17,385

27.77 Day's Range 29.00

13.48 52 Week Range 32.085

Market Cap

339.195M

Previous Close

27.77

Open

27.77

Last Trade

414

28.98

(priorref)

Last Trade Time

Financial Volume

$ 495,469

VWAP

28.4998

Average Volume (3m)

18,160

Shares Outstanding

11,704,467

Dividend Yield

PE Ratio

-8.29

Earnings Per Share (EPS)

-3.49

Revenue

4.76M

Net Profit

-40.83M

XOMA Corp is a biotechnology royalty aggregator playing a unique role in helping biotech companies achieve their goal of improving human health. XOMA acquires the potential future economics associated with pre-commercial therapeutic candidates that have been licensed to pharmaceutical or biotechnolo... XOMA Corp is a biotechnology royalty aggregator playing a unique role in helping biotech companies achieve their goal of improving human health. XOMA acquires the potential future economics associated with pre-commercial therapeutic candidates that have been licensed to pharmaceutical or biotechnology companies. When XOMA acquires future economic rights, the seller receives non-dilutive, non-recourse funding that can use to advance their internal drug candidate(s) or for general corporate purposes. Show more

Sector

Pharmaceutical Preparations

Industry

Pharmaceutical Preparations

Website

www.xoma.com

Headquarters

Wilmington, Delaware, USA

Founded

XOMA Royalty Corporation is listed in the Pharmaceutical Preparations sector of the NASDAQ with ticker XOMA. The last closing price for XOMA Royalty was $27.77. Over the last year, XOMA Royalty shares have traded in a share price range of $ 13.48 to $ 32.085.

XOMA Royalty currently has 11,704,467 shares outstanding. The market capitalization of XOMA Royalty is $325.03 million. XOMA Royalty has a price to earnings ratio (PE ratio) of -8.29.

XOMA Royalty to Present at Upcoming Investor Conferences in September

EMERYVILLE, Calif., Sept. 04, 2024 (GLOBE NEWSWIRE) -- XOMA Royalty Corporation (NASDAQ: XOMA), the biotech royalty aggregator, announced today members of its Executive Team will participate at...

XOMA Royalty Reports Second Quarter 2024 Financial Results and Highlights Recent Activities

Cash receipts totaled $22.6 million in 2Q24, inclusive of royalty income and milestones from Day One Pharmaceuticals and Rezolute Expanded the commercial royalty and milestone portfolio with the...

XOMA Declares Quarterly Preferred Stock Dividends

EMERYVILLE, Calif., June 20, 2024 (GLOBE NEWSWIRE) -- XOMA Corporation (Nasdaq: XOMA) (“XOMA” or the “Company”) today announced its Board of Directors has authorized the following cash dividends...

XOMA Receives $8.1 Million Milestone Related to Day One Biopharmaceuticals’ Sale of its Priority Review Voucher

EMERYVILLE, Calif., June 12, 2024 (GLOBE NEWSWIRE) -- XOMA Corporation (NASDAQ: XOMA), the biotech royalty aggregator, announced today it has received an $8.1 million milestone payment from...

XOMA to Present at H.C. Wainwright 2nd Annual Bioconnect Investor Conference at NASDAQ

EMERYVILLE, Calif., May 14, 2024 (GLOBE NEWSWIRE) -- XOMA Corporation (NASDAQ: XOMA), the biotech royalty aggregator, announced today that members of its Executive Team will participate in the...

XOMA Reports First Quarter 2024 Financial Results and Highlights Recent Activities

Earned $9 million milestone upon U.S. Food and Drug Administration’s approval of Day One’s OJEMDA™ (tovorafenib); XOMA is entitled to receive a mid-single digit royalty on OJEMDA™ sales Acquired...

XOMA Adds Economic Interests in Three First-in-Category Assets to its Royalty and Milestone Portfolio Including XACIATO™ (clindamycin phosphate) Vaginal Gel 2%

Organon, a global women’s healthcare company, initiated XACIATO™ commercial activities in the fourth quarter of 2023 XOMA further expands its late-stage portfolio with synthetic royalty and...

XOMA Earns $9 Million Milestone as FDA Grants Accelerated Approval to Day One’s OJEMDATM (tovorafenib) for Relapsed or Refractory BRAF-altered Pediatric Low-Grade Glioma (pLGG)

XOMA is entitled to a mid-single digit royalty on global OJEMDA™ sales First and only FDA-approved type II RAF inhibitor for patients with relapsed or refractory pLGG harboring a BRAF fusion or...

Actym Therapeutics Appoints Thomas Smart as CEO

Actym Therapeutics Appoints Thomas Smart as CEO PR Newswire BERKELEY, Calif., April 24, 2024 BERKELEY, Calif., April 24, 2024 /PRNewswire/ -- Actym Therapeutics, pioneering a new drug modality to...

XOMA Corporation Announces Closing of Tender Offer

EMERYVILLE, Calif., April 03, 2024 (GLOBE NEWSWIRE) -- XOMA Corporation (NASDAQ: XOMA) (“XOMA” or the “Company”), a biotechnology royalty aggregator playing a distinctive role in helping biotech...

Period	Change	Change %	Open	High	Low	Avg. Daily Vol	VWAP
1	1.1	3.94548063128	27.88	29.8599	25.95	22251	28.33800312	CS
4	3.53	13.8703339882	25.45	30.36	21.86	22631	27.05435389	CS
12	3.31	12.8944292949	25.67	30.36	21.27	18160	26.22112596	CS
26	13.4	86.0077021823	15.58	30.36	13.48	22172	21.65119259	CS
52	2.52	9.52380952381	26.46	32.085	13.48	29216	20.68546476	CS
156	9.84	51.4106583072	19.14	46.32	13.48	36073	24.16565196	CS
260	0	0	0	29	0	0	0	CS

Most Active
% Gainers
% Losers

Symbol	Price	Vol.
NOVVUNova Vision Acquisition Corporation	$ 41.00 (207.35%)	17.4k
NOVVNova Vision Acquisition Corporation	$ 37.0001 (200.08%)	202.75k
SMXSMX Security Matters Public Company	$ 5.85 (138.78%)	49.72M
OMICSingular Genomics Systems Inc	$ 12.38 (119.12%)	2.72M
TILInstill Bio Inc	$ 84.75 (82.41%)	3.76M
GSIWGarden Stage Ltd	$ 2.9693 (-75.66%)	4.24M
UPCUniverse Pharmaceuticals Inc	$ 0.55 (-67.07%)	30.45M
VMARVision Marine Technologies Inc	$ 0.77 (-48.67%)	34.54M
PRLDPrelude Therapeutics Inc	$ 2.775 (-42.55%)	2.49M
CNEYCN Energy Group Inc	$ 0.4335 (-37.17%)	5.06M
NVDANVIDIA Corporation	$ 119.10 (-0.03%)	238.43M
XXII22nd Century Group Inc	$ 0.3447 (28.00%)	183.73M
IMRXImmuneering Corporation	$ 2.02 (41.26%)	136.36M
SQQQProShares UltraPro Short QQQ	$ 8.17 (-1.33%)	127.78M
MULNMullen Automotive Inc	$ 0.1328 (-20.48%)	120.81M